Literature DB >> 17552384

Closed funnel-shaped proliferative vitreoretinopathy in patients with cognitive disabilities.

Takayuki Baba1, Sumiyoshi Tanaka, Akira Maesawa, Tohru Teramatsu, Yasuo Noda.   

Abstract

BACKGROUND AND
OBJECTIVE: To report severe proliferative vitreoretinopathy (PVR) cases in patients with cognitive disabilities treated with vitrectomy. PATIENTS AND METHODS: This retrospective study included 10 eyes of 9 consecutively enrolled patients with cognitive disabilities. The severity of PVR was grade C type 2345 with widespread preretinal and subretinal proliferation in all cases. The surgical management was vitrectomy with scleral buckling, retinotomy, removal of preretinal and subretinal proliferation, and silicone oil tamponade. Mandatory prone positioning and limb restraint were not indicated. Postoperative anatomic and functional success were studied. The follow-up ranged from 3 to 62 months (mean: 25.8 months).
RESULTS: The retina was attached in 10 eyes (100%) at the final examination. Functional success, based on an improvement in patient daily activity, was achieved in 4 patients (44%). No severe complications were noted.
CONCLUSIONS: Treatment with vitrectomy was effective to manage severe PVR in patients with cognitive disabilities and contributed to improve daily life.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17552384     DOI: 10.3928/15428877-20070501-02

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  2 in total

1.  Case of retinal detachment due to retinal break splitting macula vertically in a patient with cognitive disorder.

Authors:  Takayuki Baba; Tomoaki Tatsumi; Toshiyuki Oshitari; Shuichi Yamamoto
Journal:  Clin Ophthalmol       Date:  2011-03-28

Review 2.  How to help children with neurodevelopmental and visual problems: a scoping review.

Authors:  C Williams; K Northstone; C Borwick; M Gainsborough; J Roe; S Howard; S Rogers; J Amos; J M Woodhouse
Journal:  Br J Ophthalmol       Date:  2013-10-24       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.